CMPS News & Analysis

Compass Therapeutics (CMPS) Stock Price Target Cut Due to FDA Uncertainty

Stifel has reduced the stock price target for Compass Therapeutics (CMPS) amid ongoing uncertainty regarding FDA decisions. The specific new target price has not been disclosed in the article. This adjustment reflects concerns over regulatory timelines that could impact Compass's market valuation and future performance. Investors may view this downgrade as a signal to reassess risk associated with the company’s pipeline developments under FDA review.